clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Carcinoma, Lewis Lung D018827 22 associated lipids
Fibrosis D005355 23 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Nasal Polyps D009298 26 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Endometriosis D004715 29 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Diarrhea D003967 32 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Lung Diseases D008171 37 associated lipids
Arthritis D001168 41 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Psoriasis D011565 47 associated lipids
Parkinson Disease D010300 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Pain D010146 64 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Colitis D003092 69 associated lipids
Hyperlipidemias D006949 73 associated lipids
Stomach Ulcer D013276 75 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Insulin Resistance D007333 99 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hemolysis D006461 131 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Auw-Hädrich C et al. [Clarithromycin for monotherapy of B-cell MALT lymphoma?]. 2013 Ophthalmologe pmid:24231914
Formanoy E et al. Tenosynovitis of the right hand. Mycobacterium kansasii. 2013 Neth J Med pmid:24394739
Lee YC et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. 2013 Gut pmid:22698649
Amado-Rodríguez L et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. 2013 Respir. Res. pmid:23663489
Pereira JM et al. Interplay of degradation, dissolution and stabilization of clarithromycin and its amorphous solid dispersions. 2013 Mol. Pharm. pmid:24116899
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Yoon H et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? 2013 J. Gastroenterol. Hepatol. pmid:24118110
Chen K et al. Low dose macrolide administration for long term is effective for otitis media with effusion in children. 2013 Auris Nasus Larynx pmid:22673738
Drago F et al. Acute autoimmune thrombocytopenia and worsening of dermatomyositis after administration of clarithromycin. 2013 J. Am. Acad. Dermatol. pmid:24124859
Zhu D et al. Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities. 2013 Bioorg. Med. Chem. Lett. pmid:24139585
Nasa M et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. 2013 Indian J Gastroenterol pmid:24158898
Kim SY et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. 2013 J. Clin. Gastroenterol. pmid:22647826
Fagoonee S et al. Efficacy of cefixime-based triple therapy for Helicobacter pylori eradication: a retrospective study. 2013 Panminerva Med pmid:24088806
Gisbert JP et al. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. 2013 J. Clin. Gastroenterol. pmid:22647827
Piso RJ et al. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters. 2013 Swiss Med Wkly pmid:24089030
Schafranek L et al. Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. 2013 Leuk. Lymphoma pmid:22656271
Yonezawa H et al. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. 2013 PLoS ONE pmid:24039906
Gysel M et al. Torsades de pointes following clarithromycin treatment. 2013 Expert Rev Cardiovasc Ther pmid:24147515
Megraud F et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. 2013 Gut pmid:22580412
Wang S et al. A supra-monolayer nanopattern for organic nanoparticle array deposition. 2013 ACS Appl Mater Interfaces pmid:23480527
Raghunatha K and George JP Periodontal tissue and serum concentration of clarithromycin after systemic administration in patients affected by chronic periodontitis. 2013 J. Periodontol. pmid:23451987
Liang X et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. 2013 Clin. Gastroenterol. Hepatol. pmid:23376004
Calza P et al. Fate of selected pharmaceuticals in river waters. 2013 Environ Sci Pollut Res Int pmid:22851223
Morse AL et al. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. 2013 Can. J. Gastroenterol. pmid:24340314
Pan W et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. 2013 Xenobiotica pmid:22830954
Schmidt BJ and Hermansen MN [Late debut of neonatal pneumonia caused by Chlamydia trachomatis]. 2013 Ugeskr. Laeg. pmid:23428270
Tsukanov VV et al. [Helicobacter pylori eradication: current status]. 2013 Ter. Arkh. pmid:23653944
Sierra F et al. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. 2013 Aliment. Pharmacol. Ther. pmid:23656465
Radouane N et al. [Generalized chromomycosis caused by Phialophora verrucosa]. 2013 Ann Dermatol Venereol pmid:23466152
Otsuka SH Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. 2013 Pharmacotherapy pmid:23471710
Jiang JW et al. Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. 2013 Bioorg. Med. Chem. Lett. pmid:23591116
Odagiri T et al. Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. 2013 J. Med. Chem. pmid:23409972
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Laving A et al. Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya. 2013 S. Afr. Med. J. pmid:24300630
Cecchini MP et al. Might Helicobacter pylori infection be associated with distortion on taste perception? 2013 Med. Hypotheses pmid:23845559
Delgado JS et al. Granulomatous gastritis and Helicobacter pylori infection. 2013 Isr. Med. Assoc. J. pmid:23882902
Lee HJ et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. 2013 J. Infect. Dis. pmid:23801607
Bustamante-Rengifo JA et al. In vitro effect of amoxicillin and clarithromycin on the 3' region of cagA gene in Helicobacter pylori isolates. 2013 World J. Gastroenterol. pmid:24106405
Shallom SJ et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. 2013 J. Clin. Microbiol. pmid:23804391
Greupink R et al. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. 2013 Eur J Pharm Sci pmid:23806476
Kim SG et al. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. 2013 Korean J Gastroenterol pmid:23954956
Park CW et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. 2013 Int J Pharm pmid:23820131
Yoshida S et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. 2013 Int. J. Antimicrob. Agents pmid:23850022
Yu Q et al. Treatment of pulmonary mucosa-associated lymphoid tissue lymphoma with clarithromycin. 2013 Chin. Med. J. pmid:23786961
Dabirmoghaddam P et al. The efficacy of clarithromycin in patients with severe nasal polyposis. 2013 Acta Med Iran pmid:23852839
Chen PR and Tan SY [The treatment outcomes of 21 cases of rapidly growing mycobacteria related pulmonary disease]. 2013 Zhonghua Jie He He Hu Xi Za Zhi pmid:23856140
Seyedmajidi S et al. Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population. 2013 Arab J Gastroenterol pmid:23622801
Andersen JT et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. 2013 PLoS ONE pmid:23301061
Kwak HM et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. 2013 Placenta pmid:23465535
Huang HC et al. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab. 2013 Ann. Hematol. pmid:23242476
Ang TL et al. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. 2013 J Dig Dis pmid:23253473
Danilko L et al. [Clarithromycin therapy of a B cell MALT lymphoma]. 2013 Ophthalmologe pmid:23224128
Liang JH et al. Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides. 2013 Eur J Med Chem pmid:23202851
Delavenne X et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. 2013 Br J Clin Pharmacol pmid:23210726
Duman DG et al. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. 2013 Br. J. Nutr. pmid:23279717
Bessa LJ et al. Helicobacter pylori free-living and biofilm modes of growth: behavior in response to different culture media. 2013 APMIS pmid:23237527
Qvist T et al. First report of lung transplantation in a patient with active pulmonary Mycobacterium simiae infection. 2013 Transplant. Proc. pmid:23267789
Fiorini G et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. 2013 Clin. Gastroenterol. Hepatol. pmid:23267869
Kazama I and Maruyama Y Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. 2013 Pharm Biol pmid:23527897
Kawai Y et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. 2013 Antimicrob. Agents Chemother. pmid:23459497
Sardarian H et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. 2013 Helicobacter pmid:23121338
Liou JM et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. 2013 Lancet pmid:23158886
Thomas M et al. Periprosthetic atypical mycobacterial infection in breast implants: a new kid on the block! 2013 J Plast Reconstr Aesthet Surg pmid:23122691
Pandey SK et al. Antimalarial interaction of quinine and quinidine with clarithromycin. 2013 Parasitology pmid:23137860
Lahbabi M et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study. 2013 Clin Res Hepatol Gastroenterol pmid:23168228
Darwish KM et al. RP-HPLC/pre-column derivatization for analysis of omeprazole, tinidazole, doxycycline and clarithromycin. 2013 J Chromatogr Sci pmid:23081968
Uthman MM et al. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. 2013 Cochrane Database Syst Rev pmid:23633339
Secka O et al. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. 2013 Antimicrob. Agents Chemother. pmid:23263004
Simoens S et al. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. 2013 Respir Med pmid:23352223
Phunpruch S et al. A role for 16S rRNA dimethyltransferase (ksgA) in intrinsic clarithromycin resistance in Mycobacterium tuberculosis. 2013 Int. J. Antimicrob. Agents pmid:23541074
Mueck W et al. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. 2013 Br J Clin Pharmacol pmid:23305158
Alhajlan M et al. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. 2013 Antimicrob. Agents Chemother. pmid:23545534
Goh IX et al. Cytochrome P450 drug interactions with statin therapy. 2013 Singapore Med J pmid:23546024
Georgopoulos S et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. 2013 J. Clin. Gastroenterol. pmid:22858517
Malfertheiner P [Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance]. 2013 Dtsch. Med. Wochenschr. pmid:23512360
Seneviratne K and Herieka E A rifampicin-resistant Mycobacterium marinum infection in a newly diagnosed HIV-1 individual. 2013 Int J STD AIDS pmid:23512514
Ogawa K Genetic research about Mycobacterium avium complex. 2013 Kekkaku pmid:23513564
Liang JH et al. Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA. 2013 Bioorg. Med. Chem. Lett. pmid:23375796
Karmakar S et al. Hypokalemia: a potent risk for QTc prolongation in clarithromycin treated rats. 2013 Eur. J. Pharmacol. pmid:23567068
Benajah DA et al. Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). 2013 Clin Res Hepatol Gastroenterol pmid:23567104
Bolhuis MS et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. 2013 Eur. Respir. J. pmid:23520311
Schembri S et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. 2013 BMJ pmid:23525864
Matsumoto T et al. Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin. 2013 J. Gastroenterol. Hepatol. pmid:23527757
Joosten M et al. Case report: Helicobacter suis infection in a pig veterinarian. 2013 Helicobacter pmid:23551953
Howard ST Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. 2013 Tuberculosis (Edinb) pmid:24388643
Zendedel A et al. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. 2013 J Pak Med Assoc pmid:23914633
Maggi P et al. Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsycotic drugs. 2013 Immunopharmacol Immunotoxicol pmid:22804484
Haider M et al. Post-operative sinus formation due to Mycobacterium abscessus: a case report. 2013 Indian J Tuberc pmid:24000496
Hong SK et al. First case of Mycobacterium longobardum infection. 2013 Ann Lab Med pmid:24003427
Labenz J [Fewer stomach cancers after Helicobacter pylori eradication]. 2013 MMW Fortschr Med pmid:24006589
Miyauchi R et al. Clarithromycin-induced haemorrhagic colitis. 2013 BMJ Case Rep pmid:23964038
Ergül B et al. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. 2013 Helicobacter pmid:24011287
Gandhi S et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. 2013 JAMA pmid:24346990
Yu RX et al. Köebner phenomenon induced by cupping therapy in a psoriasis patient. 2013 Dermatol. Online J. pmid:24011324
Abenavoli L et al. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 2013 Med. Hypotheses pmid:24011768
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Moriya S et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. 2013 Int. J. Oncol. pmid:23546223
Akiyoshi T et al. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. 2013 Drug Metab. Pharmacokinet. pmid:23514827
Makobongo MO et al. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. 2013 PLoS ONE pmid:23935905
Unai S et al. Sternal wound infection caused by Mycobacterium chelonae. 2013 J Card Surg pmid:23941599